Impact of pharmacists on outcomes for patients with psychiatric or neurologic disorders.
interprofessional team
medication management
neurologic pharmacist
patient-level outcomes
psychiatric pharmacist
Journal
The mental health clinician
ISSN: 2168-9709
Titre abrégé: Ment Health Clin
Pays: United States
ID NLM: 101728585
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
entrez:
23
11
2020
pubmed:
24
11
2020
medline:
24
11
2020
Statut:
epublish
Résumé
Psychiatric and neurologic illnesses are highly prevalent and are often suboptimally treated. A 2015 review highlighted the value of psychiatric pharmacists in improving medication-related outcomes. There is a need to describe areas of expansion and strengthened evidence regarding pharmacist practice and patient care impact in psychiatric and neurologic settings since 2015. A systematic search of literature published from January 2014 to June 2019 was conducted. Publications describing patient-level outcome results associated with pharmacist provision of care in a psychiatric/neurologic setting and/or in relation to central nervous system (CNS) medications were included. A total of 64 publications were included. There was significant heterogeneity of published study methods and data, prohibiting meta-analysis. Pharmacists practicing across a wide variety of health care settings with focus on CNS medication management significantly improved patient-level outcomes, such as medication adherence, disease control, and avoidance of hospitalization. The most common practice approach associated with significant improvement in patient-level outcomes was incorporation of psychiatric pharmacist input into the interprofessional health care team. Pharmacists who focus on psychiatric and neurologic disease improve outcomes for patients with these conditions. This is important in the current health care environment as most patients with psychiatric or neurologic conditions continue to have unmet needs. Additional studies designed to measure pharmacists' impact on patient-level outcomes are encouraged to strengthen these findings.
Identifiants
pubmed: 33224694
doi: 10.9740/mhc.2020.11.358
pii: MHC-D-20-00005
pmc: PMC7653731
doi:
Types de publication
Journal Article
Langues
eng
Pagination
358-380Informations de copyright
© 2020 CPNP. The Mental Health Clinician is a publication of the College of Psychiatric and Neurologic Pharmacists.
Déclaration de conflit d'intérêts
Disclosures: S.H.P. is a paid consultant for Wolters Kluwer Health. Otherwise the authors have no relevant financial or other conflicts of interest to disclose.
Références
Drugs Aging. 2018 Feb;35(2):153-161
pubmed: 29396715
Ment Health Clin. 2018 Mar 23;7(3):101-105
pubmed: 29955506
World Psychiatry. 2011 Feb;10(1):52-77
pubmed: 21379357
Cochrane Database Syst Rev. 2010 Jul 07;(7):CD000336
pubmed: 20614422
Int J Clin Pharm. 2017 Dec;39(6):1228-1236
pubmed: 28905171
Ment Health Clin. 2018 Nov 1;8(6):317-321
pubmed: 30397575
Subst Abus. 2018;39(2):190-192
pubmed: 29558338
Diabet Med. 2017 Jul;34(7):916-924
pubmed: 27973692
Prim Care Companion CNS Disord. 2014 Oct 30;16(5):
pubmed: 25667811
Popul Health Manag. 2018 Oct;21(5):366-372
pubmed: 29211661
Ment Health Clin. 2019 May 10;9(3):138-140
pubmed: 31123662
Drugs Aging. 2015 Aug;32(8):663-70
pubmed: 26248475
J Gen Intern Med. 2006 Nov;21(11):1133-7
pubmed: 17026726
J Am Pharm Assoc (2003). 2015 Mar-Apr;55(2):187-92
pubmed: 25749264
Saudi Pharm J. 2018 Dec;26(8):1204-1207
pubmed: 30510473
J Prim Care Community Health. 2016 Apr;7(2):118-21
pubmed: 26582045
PLoS One. 2015 Nov 06;10(11):e0142011
pubmed: 26544202
J Manag Care Spec Pharm. 2017 Jan;23(1):74-84
pubmed: 28025928
Health Serv Res. 2018 Aug;53(4):2547-2566
pubmed: 28891153
Prim Care Companion CNS Disord. 2018 May 31;20(3):
pubmed: 29873949
J Opioid Manag. 2014 May-Jun;10(3):159-68
pubmed: 24944066
Am J Health Syst Pharm. 2017 Dec 1;74(23 Supplement 4):S90-S94
pubmed: 29167145
Int J Clin Pharm. 2019 Feb;41(1):42-48
pubmed: 30610545
Int Clin Psychopharmacol. 2015 Nov;30(6):316-9
pubmed: 26163876
Pharmacotherapy. 2013 Aug;33(8):888-91
pubmed: 23625823
J Am Pharm Assoc (2003). 2017 Mar - Apr;57(2S):S135-S140
pubmed: 28292501
Psychopharmacol Bull. 2018 Feb 5;48(2):18-28
pubmed: 29713097
Age Ageing. 2018 May 01;47(3):430-437
pubmed: 29432518
Neurol Clin Pract. 2020 Feb;10(1):65-72
pubmed: 32190422
J Clin Pharm Ther. 2017 Aug;42(4):502-505
pubmed: 28488314
J Am Geriatr Soc. 2019 Jan;67(1):115-118
pubmed: 30300947
Springerplus. 2015 Sep 02;4:470
pubmed: 26357601
J Clin Pharm Ther. 2016 Aug;41(4):414-8
pubmed: 27255463
BMC Geriatr. 2019 Jan 8;19(1):7
pubmed: 30621606
Patient Prefer Adherence. 2017 May 18;11:959-964
pubmed: 28572723
Int J Clin Pharm. 2016 Feb;38(1):30-3
pubmed: 26659084
BMC Psychiatry. 2015 Sep 16;15:219
pubmed: 26376830
J Pharm Pract. 2019 Aug;32(4):434-441
pubmed: 29486664
Health Qual Life Outcomes. 2014 Oct 31;12:162
pubmed: 25358723
J Pharm Pract. 2017 Aug;30(4):425-433
pubmed: 27480874
Ment Health Clin. 2018 Mar 23;7(3):111-115
pubmed: 29955508
PLoS One. 2015 Oct 05;10(10):e0139302
pubmed: 26437449
Fam Syst Health. 2016 Jun;34(2):104-13
pubmed: 26986622
Lancet Neurol. 2018 Nov;17(11):939-953
pubmed: 30287051
J Clin Pharm Ther. 2017 Jun;42(3):329-336
pubmed: 28317138
Pharm Pract (Granada). 2015 Apr-Jun;13(2):553
pubmed: 26131043
Fed Pract. 2016 Mar;33(Suppl 2):22S-25S
pubmed: 30766208
Clin Neuropharmacol. 2018 Jan/Feb;41(1):14-19
pubmed: 29300205
Am J Health Syst Pharm. 2017 Feb 15;74(4):253-262
pubmed: 28179250
Integr Pharm Res Pract. 2018 Oct 26;7:161-171
pubmed: 30464898
Hosp Pharm. 2019 Jun;54(3):180-185
pubmed: 31205329
J Opioid Manag. 2016 Nov/Dec;12(6):389-395
pubmed: 28059431
Am J Health Syst Pharm. 2013 Feb 15;70(4):366-7
pubmed: 23370144
Ment Health Clin. 2016 Aug 31;6(5):260-265
pubmed: 29955480
Health Promot Pract. 2014 Jul;15(4):512-20
pubmed: 24231631
Int J Clin Pharm. 2014 Apr;36(2):222-32
pubmed: 24306436
Ment Health Clin. 2019 Mar 1;9(2):70-75
pubmed: 30842913
Ment Health Clin. 2018 Mar 23;7(3):116-123
pubmed: 29955509
BMC Health Serv Res. 2016 Apr 26;16:150
pubmed: 27117589
BMC Psychiatry. 2016 Aug 30;16:303
pubmed: 27577925
Epilepsia. 2017 Jan;58(1):17-26
pubmed: 27888514
J Am Pharm Assoc (2003). 2018 Jul - Aug;58(4S):S24-S29.e2
pubmed: 30006184
Seizure. 2019 Jul;69:147-153
pubmed: 31048271
J Ment Health. 2018 Apr;27(2):164-173
pubmed: 28675321
J Clin Psychiatry. 2017 Nov/Dec;78(9):e1270-e1275
pubmed: 29178683
J Manag Care Spec Pharm. 2016 Nov;22(11):1330-1336
pubmed: 27783555
Alzheimers Res Ther. 2017 May 23;9(1):36
pubmed: 28535785
Front Pharmacol. 2017 Oct 10;8:722
pubmed: 29066976
Epilepsy Behav. 2014 Aug;37:157-64
pubmed: 25022824
Fed Pract. 2017 Oct;34(Suppl 8):S32-S37
pubmed: 30766314
Eur J Clin Pharmacol. 2017 Jul;73(7):827-835
pubmed: 28391409